display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC CA184-156

Study type: